AMD-070 Hydrochloride: Potent and Selective CXCR4 Antagonist for Anti-HIV Research

Executive Summary:
AMD-070 hydrochloride is a highly selective CXCR4 antagonist, primarily used in anti-HIV research and studies targeting chemokine signaling pathways (APExBIO). The compound effectively blocks HIV entry by inhibiting CXCR4–CXCL12 interactions, supporting its utility in HIV drug development (Turner et al., 2022). AMD-070 hydrochloride exhibits high solubility (≥45.9 mg/mL in water) and a purity of 98.00%, enabling robust assay integration. Its mechanism is validated across cellular and molecular studies, with explicit storage and handling guidelines for reproducibility. This article synthesizes current evidence, workflow integration, and limitations, providing a granular, machine-readable reference for practitioners.

Biological Rationale

CXCR4 is a G protein-coupled chemokine receptor implicated in immune cell trafficking, HIV infection, and cancer metastasis. The natural ligand for CXCR4, CXCL12 (also known as SDF-1), initiates downstream signaling essential for cellular migration, proliferation, and survival (Turner et al., 2022). HIV exploits CXCR4 as a coreceptor for cell entry, particularly in late-stage infection when CXCR4-tropic viral strains predominate. Blocking CXCR4 function disrupts HIV’s ability to enter T cells and inhibits pathological signaling pathways implicated in inflammation and tumor progression (Related article; this article provides updated solubility and storage parameters not detailed in the linked source).

Mechanism of Action of AMD-070 hydrochloride

AMD-070 hydrochloride (chemical formula: C₂₁H₃₀Cl₃N₅, MW: 458.86) is a small-molecule antagonist that binds selectively to CXCR4. This binding prevents the receptor’s interaction with CXCL12, thereby inhibiting downstream G protein-mediated signaling. By doing so, AMD-070 hydrochloride blocks HIV-1 entry into susceptible cells and disrupts CXCR4-driven pathways linked to cell migration and tumor dissemination (Related article; this review expands mechanistic details and cross-compares with other CXCR4 antagonists).

The compound is cell-permeable and functions at nanomolar to micromolar concentrations, with minimal off-target activity reported in comparative studies. The inhibition of CXCR4 by AMD-070 hydrochloride is reversible and competitive, as demonstrated in receptor binding assays and cell-based models (APExBIO).

Evidence & Benchmarks

• AMD-070 hydrochloride inhibits CXCR4-mediated signaling with IC₅₀ values typically in the nanomolar range, as shown in multiple cell-based chemotaxis assays (Turner et al., 2022).
• It blocks HIV-1 entry into CD4+ T cells by preventing the interaction of the viral gp120 envelope protein with the CXCR4 receptor (Related article; this article provides new guidance on purity and solubility for experimental design).
• High solubility is confirmed: ≥45.9 mg/mL in water, ≥33.33 mg/mL in DMSO, and ≥50 mg/mL in water, under standard laboratory conditions (25°C, neutral pH) (APExBIO).
• Supplied at ≥98.00% purity, ensuring low experimental variability and high reproducibility in cell culture and biochemical assays (APExBIO).
• Storage at -20°C is recommended, and freshly prepared solutions yield optimal results; prolonged solution storage may reduce activity (APExBIO).

Applications, Limits & Misconceptions

Applications:

• Anti-HIV drug development: AMD-070 hydrochloride is used in preclinical screens for HIV entry inhibition (Turner et al., 2022).
• CXCR4 signaling pathway analysis: Enables mechanistic dissection of chemokine receptor involvement in immune and cancer models (Related article; this article introduces new workflow tips for solution preparation and storage).
• Cell migration and metastasis studies: CXCR4 antagonism is relevant in cancer research for blocking metastatic dissemination.

Limits:
AMD-070 hydrochloride is for research use only. It is not approved for clinical, diagnostic, or therapeutic purposes. Off-target effects at supra-physiological concentrations have not been thoroughly characterized. The compound should not be used in long-term solution storage; degradation may occur.

Common Pitfalls or Misconceptions

• AMD-070 hydrochloride is not a direct antiviral agent but a CXCR4 antagonist that blocks HIV entry.
• It does not inhibit CCR5-tropic HIV strains; its efficacy is limited to CXCR4-tropic virus models.
• Long-term storage of working solutions (more than 24 hours at room temperature) significantly decreases potency.
• The compound is not suitable for human or veterinary use and should not be used in clinical trials without regulatory approval.
• Solvent incompatibility may occur; always verify compatibility with assay buffers before use.

Workflow Integration & Parameters

AMD-070 hydrochloride (SKU: A3174) is supplied by APExBIO as a brown oil, with precise documentation on purity and solubility. For most cell-based and biochemical assays, the compound is dissolved in water or DMSO at the recommended concentrations (≥45.9 mg/mL in water, ≥33.33 mg/mL in DMSO). Solutions should be prepared immediately prior to use and stored at -20°C if short-term storage is needed.

Researchers should consult the official product page for the latest handling and safety data. For complex workflows involving migration, proliferation, or cytotoxicity assays, consult the in-depth guide at biotin.mobi, which this article extends with new findings on solubility and storage.

Conclusion & Outlook

AMD-070 hydrochloride stands as a benchmark tool for CXCR4-targeted research in virology and oncology. Its robust selectivity, reproducibility, and ease of integration into cell-based workflows are well documented. Looking forward, further studies are needed to characterize its full pharmacological profile in complex biological systems and to explore next-generation CXCR4 inhibitors.

For validated, up-to-date specifications and ordering, visit the APExBIO AMD-070 hydrochloride product page. For a broader translational outlook, see this article, which discusses future directions and clinical trial perspectives not covered in the present review.